Syros Pharmaceuticals (SYRS) Upgraded at BidaskClub

Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday.

A number of other brokerages also recently commented on SYRS. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Tuesday, July 17th. Roth Capital upgraded Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday. Zacks Investment Research upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Friday, August 10th. Cann reiterated a “buy” rating and issued a $26.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, November 1st. Finally, JMP Securities set a $33.00 price objective on Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $19.00.

SYRS opened at $7.95 on Tuesday. The company has a market capitalization of $261.16 million, a price-to-earnings ratio of -3.73 and a beta of 0.78. Syros Pharmaceuticals has a 12-month low of $6.25 and a 12-month high of $15.88.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, November 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.02). The business had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.72 million. Equities research analysts forecast that Syros Pharmaceuticals will post -1.86 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter worth approximately $119,000. The Manufacturers Life Insurance Company lifted its position in shares of Syros Pharmaceuticals by 299.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock worth $168,000 after acquiring an additional 9,691 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter worth approximately $134,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter worth approximately $177,000. Finally, Citadel Advisors LLC bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter worth approximately $186,000. Institutional investors own 60.74% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Article: Yield Curve

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply